<DOC>
	<DOC>NCT02693522</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of recombinant human growth hormone on adult growth hormone deficiency</brief_summary>
	<brief_title>Evaluation of Efficacy and Safety of Recombinant Somatroipn in Patients With Growth Hormone Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism, Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Patients aged 18 and up Patients with maximum serum growth hormone concentration of less than 5 ng/ml Patients who can successfully complete this study based on appropriate medical judgment or who expect to benefit from this study Persons who have agreed in writing to participate in this study Persons who are currently under treatment after being diagnosed with a malignant tumor Hepatosis Renal function disorder Intracranial hypertension Proliferative diabetic retinopathy Persons who carry acromegaly activity Fertile women who are not pregnant or who do not take appropriate contraceptive measures and whose urine tested positive for hCG (human Chorionic Gonadotropin) Mental patients and/or drug addicts and alcoholics Patients who had participated in the other drug study within the last 30 days prior to participating in this study Patients considered unfit for this study by the attending physician</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>